ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO802

GX-E2 versus CERA for Anemia in Patients Receiving Maintenance Peritoneal Dialysis: A Phase 2, Randomized, Multi-Center, Active-Comparator, Dose-Finding Safety and Efficacy Study

Session Information

Category: Dialysis

  • 605 Dialysis: Anemia and Iron Metabolism

Authors

  • Ko, Eun jeong, Seoul St. Mary's Hospital, Seoul, Korea (the Republic of)
  • Chung, Byung ha, Seoul St. Mary's Hospital, Seoul, Korea (the Republic of)
  • Shin, Sug kyun, Ilsan Hospital NHIS, Gyeonggi, Korea (the Republic of)
  • Kim, Hyung Wook, St. Vincent's Hospital, Gyeonggi, Korea (the Republic of)
  • Shin, Byung chul, Chosun University, Gwangju, Korea (the Republic of)
  • Shin, Seok Joon, Incheon St. Mary's Hospital, Gyeonggi, Korea (the Republic of)
  • Park, Hyeong cheon, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
  • Kang, Young Sun, Korea University Medical College Ansan Hospital, Gyeonggi, Korea (the Republic of)
  • Lee, Sang-Ho, Kyung Hee University Hospital, Seoul, Korea (the Republic of)
  • Song, Ho Cheol, Incheon St. Mary's Hospital, Gyeonggi, Korea (the Republic of)
  • Kim, Su Hyun, Chung-Ang University Hospital, Seoul, Korea (the Republic of)
  • Na, Ki Young, Seoul National University Bundang Hospital, Gyeonggi, Korea (the Republic of)
  • Jo, Young-Il, Konkuk University Hospital, Seoul, Korea (the Republic of)
  • Kim, Won, Chobuk National Univeristy Medical School, Jeonju, Korea (the Republic of)
  • Seong, Eun Young, Pusan National University Hospital, Busan, Korea (the Republic of)
  • Kim, Yong-Lim, Kyungpook National University Hospital, Daegu, Korea (the Republic of)
  • Heo, Minkyu, Genexine, Inc., Seongnam-si, Korea (the Republic of)
  • Woo, Jungwon, Genexine, Inc., Seongnam-si, Korea (the Republic of)
  • Yang, Chul Woo, Seoul St. Mary's Hospital, Seoul, Korea (the Republic of)
Background

GX-E2 is hybrid Fc (hyFc)-fused long-acting recombinant human erythropoietin. We conducted a phase 2, randomized, active-comparator, safety and efficacy study in patients with anemia receiving maintenance peritoneal dialysis.

Methods

Patients with a stable end-stage renal disease treated with peritoneal dialysis were included. In Part A, a dose-finding study was conducted in 60 subjects with 4-week treatment of six different dosage of GX-E2. In Part B, 12-week treatment was conducted in 72 individuals with two selected doses of GX-E2 based on the Part A results, and with methoxy polyethylene glycol-epoetin β (CERA) (0.6 μg/kg bi-weekly). Primary endpoint was mean hemoglobin change from baseline to the end of treatment.

Results

In Part A, mean Hb level was significantly increased after 4 weeks GX-E2 administration and mean Hb changes from baseline were 0.6±1.3 g/dL in 3 μg/kg, 1.3±1.1 g/dL in 5 μg/kg, and 1.4±1.0 g/dL in 8 μg/kg bi-weekly. In Part B, participants were randomly assigned to 3 groups, treated bi-weekly with 5 μg/kg, 8 μg/kg of GX-E2 and 0.6 μg/kg of CERA. Mean Hb level changes after 12 weeks GX-E2 administration were 2.2±1.3 g/dL in 5 μg/kg, 3.1±1.1 g/dL in 8 μg/kg, and 1.7±1.4 g/dL in CERA, GX-E2 showed comparable or better outcome compared to CERA (p-values for each 0.233, <0.001). No safety issues were observed.

Conclusion

In this phase 2 study of anemia treatment in patients with end-stage renal disease on maintenance peritoneal dialysis, GX-E2 was well-tolerated and effectively maintained Hb levels.(grant number: HI14C1038)

Funding

  • Commercial Support